scholarly journals Structural insights into the enzyme catalysis from comparison of three forms of dissimilatory sulphite reductase from Desulfovibrio gigas

2010 ◽  
Vol 78 (5) ◽  
pp. 1101-1116 ◽  
Author(s):  
Yin-Cheng Hsieh ◽  
Ming-Yih Liu ◽  
Vincent C.-C. Wang ◽  
Yen-Lung Chiang ◽  
En-Huang Liu ◽  
...  
2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Hong-Hsiang Guan ◽  
Yin-Cheng Hsieh ◽  
Pei-Ju Lin ◽  
Yen-Chieh Huang ◽  
Masato Yoshimura ◽  
...  

2011 ◽  
Vol 67 (a1) ◽  
pp. C774-C774
Author(s):  
C. -J. Chen ◽  
Y. -C. Hsieh ◽  
M. -Y. Liu ◽  
V. C. -C. Wang ◽  
S. I. Chan

Author(s):  
Parth Sarthi Sen Gupta ◽  
Satyaranjan Biswal ◽  
Saroj Kumar Panda ◽  
Abhik Kumar Ray ◽  
Malay Kumar Rana

<p>While an FDA approved drug Ivermectin was reported to dramatically reduce the cell line of SARS-CoV-2 by ~5000 folds within 48 hours, the precise mechanism of action and the COVID-19 molecular target involved in interaction with this in-vitro effective drug are unknown yet. Among 12 different COVID-19 targets studied here, the RNA dependent RNA polymerase (RdRp) with RNA and Helicase NCB site show the strongest affinity to Ivermectin amounting -10.4 kcal/mol and -9.6 kcal/mol, respectively. Molecular dynamics of corresponding protein-drug complexes reveals that the drug bound state of RdRp with RNA has better structural stability than the Helicase NCB site, with MM/PBSA free energy of -135.2 kJ/mol, almost twice that of Helicase (-76.6 kJ/mol). The selectivity of Ivermectin to RdRp is triggered by a cooperative interaction of RNA-RdRp by ternary complex formation. Identification of the target and its interaction profile with Ivermectin can lead to more powerful drug designs for COVID-19 and experimental exploration. </p>


Sign in / Sign up

Export Citation Format

Share Document